Medivir
Medivir Q4’20: Focus Turns to MIV-818 (Redeye)
2021-03-01 07:20
Redeye reiterates its base case for Medivir following the Q4’20 report. Upcoming MIV-818 updates will determine share sentiment, and we remain cautiously optimistic.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se